New drug aims to stop EBV in kidney transplants

NCT ID NCT07368153

Not yet recruiting Prevention Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether an IDO-1 inhibitor can safely prevent Epstein-Barr virus (EBV) infection in kidney transplant recipients who have never had EBV but receive a kidney from an EBV-positive donor. Nine participants will receive either the drug or a placebo for 28 days, alongside standard care, and be monitored for side effects and viral changes. The goal is to see if the drug is safe and tolerable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IDO-1 inhibitor
What this could lead to: If it works, this could help prevent serious EBV-related complications in kidney transplant patients who are at risk.
What could go wrong: This is a very small early-phase trial with only 9 participants, so results may not apply broadly. The drug may cause side effects or fail to prevent EBV infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EBV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Epstein-Barr virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EBV INFECTIONS KIDNEY TRANSPLANT

Contacts and locations

Locations

University Hospital Basel

Basel, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.